Abstract
Treatment standards or guidelines have been developed for most features of Parkinson’s disease (PD). However, data on the actual treatment that is put into practice are scarce. In 2000, a nationwide survey on the topic of sudden onset of sleep (SOS) in PD was initiated among the members of the German patient support group (deutsche Parkinson–Vereinigung, dPV). A part of this mailed questionnaire survey covering the antiparkinsonian and concomitant medication of the participants is presented here. This study analyses data sets from more than 6,500 PD patients. The mean dopaminergic dose was equivalent to 599 ± 387 mg levodopa/die. The most frequently administered drugs were levodopa (94.2 %), dopamine agonists (DA) (71.7 %), amantadine (40.1 %), selegiline (27.6 %), entacapone (20.4 %), budipine (12.3 %), and anticholinergics (11.8 %). Costs of pharmacotherapy were estimated to be approximately € 399 million/year in Germany. PD drug therapy in general strongly depended on age, disease duration, and the level of care. The treatment guidelines were apparently not consistently followed underlining the need for their continuous propagation throughout the medical community. In addition our data suggest that non–motor symptoms in PD are not adequately treated and that concomitant sedative medication contributes to the occurrence of SOS.
Similar content being viewed by others
References
Askmark H, Antonov K, Aquilonius SM (2003) The increased utilisation of dopamine agonists and the introduction of COMT inhibitors have not reduced levodopa consumption–a nation-wide perspective in Sweden. Parkinsonism Relat Disord 9:271–276
Brandstädter D, Oertel WH (2003) Depression in Parkinson’s disease. Adv Neurol 91:371–381
Dodel RC, Berger K, Oertel WH (2001) Health-related quality of life and healthcare utilisation in patients with Parkinson’s disease: impact of motor fluctuations and dyskinesias. Pharmacoeconomics 19:1013–1038
Dodel RC, Singer M, Köhne-Volland R, Szucs T, Rathay B, Scholz E, Oertel WH (1998) The economic impact of Parkinson’s disease. An estimation based on a 3-month prospective analysis. Pharmacoeconomics 14:299–312
Donnan PT, Steinke DT, Stubbings C, Davey PG, MacDonald TM (2000) Selegiline and mortality in subjects with Parkinson’s disease. Neurology 55:1785–1789
Hoehn MM, Yahr MD (1967) Parkinsonism: onset, progression and mortality. Neurology 17:427–442
Bundesverband der pharmazeutischen Industrie (2000) Rote Liste. Rote Liste Verlag, Weinheim
Johns MW (1991) A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 14:540–545
Körner Y, Meindorfner C, Möller JC, Stiasny-Kolster K, Haja D, Cassel W, Oertel WH, Krüger HP (2004) Predictors of sudden onset of sleep. Mov Disord 19:1279–1284
Leoni O, Martignoni E, Cosentino M, Michielotto D, Calandrella D, Zangaglia R, Riboldazzi G, Oria C, Lecchini S, Nappi G, Frigo G (2002) Drug prescribing patterns in Parkinson’s disease: a pharmacoepidemiological survey in a cohort of ambulatory patients. Pharmacoepidemiol Drug Saf 11:149–157
LePen C, Wait S, Moutard-Martin F, Dujardin M, Ziegler M (1999) Cost of illness and disease severity in a cohort of French patients with Parkinson’s disease. Pharmacoeconomics 16:59–69
Lienert GA, Krauth J (1974) Die Konfigurationsanalyse. IX. Auswertung multivariater klinischer Untersuchungspläne (Teil 1). Zeitschr Klin Psychol Psychother 22:3–17
Lozano AM, Lang AE, Galvez-Jimenez N, Miyasaki J, Duff J,Hutchinson WD, Dostrovsky JO (1995) Effect of GPi pallidotomy on motor function in Parkinson’s disease. Lancet 346: 1383–1387
Meissner W, Trottenberg T, Klaffke S, Paul G, Kuhn AA, Arnold G, Einhäupl KM, Kupsch A (2001) Apomorphine therapy versus deep brain stimulation. Clinical and economic aspects in patients with advanced Parkinson’s disease. Nervenarzt 72:924–927
Moro E, Scerrati M, Romito LMA, Roselli R, Tonali P, Albanese A (1999) Chronic subthalamic nucleus stimulation reduces medication requirements in Parkinson’s disease. Neurology 53:85–90
Klinische “Leitlinien” der Deutschen Gesellschaft für Neurologie (2003) Leitlinien für Diagnostik und Therapie in der Neurologie. Thieme, Stuttgart
Oertel WH, Quinn N (2002) Parkinsonism. In: Brandt T, Diener HC, Caplan LR (eds) Neurological disorders: course and treatment. Academic Press, San Diego, pp 1021–1079
Oertel WH, Quinn NP (1996) Parkinsonism. In: Brandt T, Caplan LR, Dichgans J, Diener HC, Kennard C (eds) Neurological Disorders – Course and Treatment. Academic Press, San Diego, pp 715–772
Olanow CW, Watts RL, Koller WC (2001) An algorithm (decision tree) for the management of Parkinson’s disease: treatment guidelines. Mov Disord 56:S1–S88
Pfeiffer RF (2003) Gastrointestinal dysfunction in Parkinson’s disease. Lancet Neurol 2:107–116
Schwabe U (2001) Parkinsonmittel. In: Schwabe U, Paffrath D (eds) Arzneiverordnungsreport 2001. Springer, Berlin, pp 591–596
Shabnam GN, Th C,Kho D, H R, Ce C (2003) Therapies for depression in Parkinson’s disease. Cochrane Database Syst Rev:CD003465
Siddiqui MF, Rast S, Lynn MJ, Auchus AP, Pfeiffer RF (2002) Autonomic dysfunction in Parkinson’s disease: a comprehensive symptom survey. Parkinsonism Relat Disord 8:277–284
Singer C (1998) Urinary dysfunction in Parkinson’s disease. Clin Neurosci 5:78–86
Singer C, Weiner WJ, Sanchez-Ramos JR (1992) Autonomic dysfunction in men with Parkinson’s disease. Eur Neurol 32:134–140
Slaughter JR, Slaughter KA, Nichols D, Holmes SE, Martens MP (2001) Prevalence, clinical manifestations, etiology, and treatment of depression in Parkinson’s disease. J Neuropsychiatry Clin Neurosci 13:187–196
Spottke EA, Martin R, Berger K, Machat O, Oertel WH, Dodel RC (2002) Healthcare utilization and economic impact of Parkinson’s disease. Mov Disord 17(Suppl 5):S142
Spottke EA, Reuter M,Machat B, Bornschein B, Campenhausen S, Berger K, Koehne-Volland RK, Rieke J, Simonow A, Brandstädter D, Siebert U, Oertel WH, Dodel RD. Cost of illness and its predictors for Parkinson’s disease in Germany. Pharmacoeconomics: in press
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Möller, J.C., Körner, Y., Dodel, R.C. et al. Pharmacotherapy of Parkinson’s disease in Germany. J Neurol 252, 926–935 (2005). https://doi.org/10.1007/s00415-005-0784-1
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00415-005-0784-1